Richard Whitley

Dr. Richard Whitley


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in The Lancet
Verified
Journal Article
Closed access
RWRichard Whitley
Richard Whitley
BRBernard Roizman
Bernard Roizman

1 February 2001 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
RWRichard Whitley
Richard Whitley
FHFrederick G. Hayden
Frederick G. Hayden
KRKeith S. Reisinger
Keith S. Reisinger
NYNancy Young
Nancy Young
RDRegina Dutkowski
Regina Dutkowski
PWPenelope Ward
Penelope Ward
Oral oseltamivir administration is effective treatment for influenza in adults. This study was conducted to determine the efficacy, safety and tolerability of oseltamivir in children with influenza. In this randomized, double blind, placebo-controlled study, children 1 through 12 years with fever [≥100°F (≥38°C)] and a history of cough or coryza <48 h duration received oseltamivir 2 mg/kg/dose or placebo twice daily for 5 days. The primary efficacy endpoint was the time to resolution of illness including mild/absent cough and coryza mild/absent, return to normal activity and euthermia. Of 695 enrolled children 452 (65%) had influenza (placebo, n = 235; oseltamivir, n = 217). Among infected children the median duration of illness was reduced by 36 h (26%) in oseltamivir compared with placebo recipients (101 h; 95% confidence interval, 89 to 118 vs. 137 h; 95% confidence interval, 125 to 150;P < 0.0001). Oseltamivir treatment also reduced cough, coryza and duration of fever. New diagnoses of otitis media were reduced by 44% (12%vs. 21%). The incidence of physician-prescribed antibiotics was significantly lower in influenza-infected oseltamivir (68 of 217, 31%) than placebo (97 of 235, 41%;P = 0.03) recipients. Oseltamivir therapy was generally well-tolerated, although associated with an excess frequency of emesis (5.8%). Discontinuation because of adverse events was low in both groups (1.8% with oseltamivir vs. 1.1% with placebo). Oseltamivir treatment did not affect the influenza-specific antibody response. Oral oseltamivir administration is an efficacious and well-tolerated therapy for influenza in children when given within 48 h of onset of illness.

1 September 2006 in Antiviral Research
Verified
Journal Article
Closed access
RWRichard Whitley
Richard Whitley

1 March 2017 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
JGJohn W. Gnann
John W. Gnann
RWRichard Whitley
Richard Whitley

1 January 2005 in Seminars in Pediatric Infectious Diseases
Verified
Journal Article
Closed access
RWRichard Whitley
Richard Whitley
DKDavid W. Kimberlin
David W. Kimberlin

11 May 1998 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
RWRichard Whitley
Richard Whitley
MJMark A. Jacobson
Mark A. Jacobson
DFDorothy N. Friedberg
Dorothy N. Friedberg
GHGary N. Holland
Gary N. Holland
DJDouglas A. Jabs
Douglas A. Jabs
HKHarold A. Kessler
Harold A. Kessler
Objective To provide recommendations for the treatment of acquired immunodeficiency syndrome–related cytomegalovirus (CMV) end-organ diseases, including retinitis, colitis, pneumonitis, and neurologic diseases. Participants A 17-member panel of physicians with expertise in clinical and virological research and in-patient care in the field of CMV diseases. Evidence Available clinical and virological study results. Recommendations are rated according to the quality and strength of available evidence. Recommendations were limited to the treatment of CMV diseases; prophylaxis recommendations are not included. Process The panel was convened in February 1997 and met regularly through November 1997. Subgroups of the panel summarized and presented available information on specific topics to the full panel; recommendations and ratings were determined by group consensus. Conclusions Although the epidemiological features of CMV diseases are changing in the setting of potent, combination antiretroviral therapy, continued attention must be paid to CMV diseases in patients infected with the human immunodeficiency virus to prevent irreversible end-organ dysfunction. The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others. Management of relapse or refractory retinitis must be likewise individualized. Ophthalmologic screening for patients at high risk for retinitis or who have a prior diagnosis of extraretinal disease is recommended. Recommendations for gastrointestinal, pulmonary, and neurologic manifestations are included.